China’s Ministry of Commerce on Monday approved Nokia’s proposed acquisition of French rival Alcatel-Lucent with conditions, almost completing the 15.6 billion euro deal’s antitrust process.
The ministry said the Finnish telecom network equipment maker had agreed to meet certain terms by Dec. 10, mainly relating to the use of wireless telecommunication standards and patent licensing.
The terms were imposed in keeping with China’s anti-monopoly regulation to ensure market competition isn’t harmed by the takeover, it added in a statement on its website.
As part of its talks with China, Nokia in August agreed to create a joint venture, Nokia Shanghai Bell, with China’s state-owned Huaxin.
“We look forward to maintaining our deep commitment to China and playing a key role in the country’s shift towards an innovation-driven economy,” Nokia chief executive Rajeev Suri said in a statement on Monday.
Nokia and Alcatel still need formal approval from the French government, after which Nokia will proceed with its all-share offer. The takeover is expected to close in the first half of 2016.
Full content: The Financial Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan